GlobeNewswire

Surge in Management Liability Claims Driven by Harassment Highlights Latest Clements Worldwide Risk Index Findings

Dela

NGOs and international schools are the leading industries experiencing loss from this growing trend

 

Washington, DC, April 19, 2018 (GLOBE NEWSWIRE) -- The rise of professional and management liability due to global harassment and abuse claims is a leading cause of loss and risk among global organizations, according to the 2018 Clements Worldwide Risk Index, released today in Lagos, Nigeria in an event held in collaboration with the U.S. Embassy in Nigeria.

The survey, which is released annually, found that 17 percent of the organizations surveyed shared they were subject to a lawsuit or litigation within the last six months, with industries such as international schools (28 percent), government agencies (25 percent) and government contractors (29 percent) the most impacted by this loss.  Twenty-seven percent of NGOs and UN agencies reported that they had suffered a significant loss from professional and management liability. 

The focus on professional and management liability risks, which also includes gender pay gap and duty of care, by NGOs and international schools are new to the top featured losses and concerns of the survey, and threaten the quality of education and services provided to students and beneficiaries of their care. This coupled with emerging threats such as natural disasters, which cost the world $306 billion according to Swiss Re, nearly double the cost of 2016, and legislation posing greater challenges to program and school operations, data protection and infrastructure, make life challenging for these industries.

"Having worked in this business for over 30 years, I thought that nothing surprises me anymore, but we did not anticipate seeing such a surge in management liability claims and for it to be such a huge loss for our primary two segments - NGOs and international schools," said Dan Tuman, President, Clements Worldwide. "In today's social climate, these trends make a clear case for organizations and industries everywhere to take steps to adapt their policies accordingly and prepare for the unexpected as no one is immune to risk."

And while respondents have shifted their attention to other losses besides political violence, more than 35 percent of respondents still express worry over increased threats of political violence and disruptions from elections or political environment, up from 27 percent last year. More conflict seems likely given the existing civil wars in Syria and Yemen, Al Shabaab in East Africa and Al Qaeda in West Africa.

Furthermore, political violence and disruption may present challenges leading up to some of the important elections on the schedule this year, including the Pakistani general election, Mexican presidential election and South Sudan general election this summer; and the Thailand general election, The Democratic Republic of Congo election and United States midterm elections later this year.

Among other results reported, almost a third of respondents said that a disruption due to terrorism is likely to happen in the next six to 12 months, with 58 percent of government agencies reporting terrorism as a significant concern.

Additionally, legislation and regulatory risk remains a primary concern with nearly 37 percent believing there will be an increase in bureaucracy for business processes and specific industries like NGOs and UN organizations sharing that nearly one in four had experienced high losses from changes in regulation.

These facts reinforce that last year's global legislation and political leadership worries surrounding the rise of nationalism, trade barriers and fluctuating currencies have been replaced this year with the United States increasing tariffs on steel and aluminum, greater deregulation and protectionism by President Trump, Brexit and renewed fallout from elections; and it may get worse before it gets better.

However, the culmination of these critical risks has not deterred an overwhelming majority of respondents surveyed from expanding their international operations, with only 13 percent saying they would delay, down from 37 percent last year, which reinforces that organizations are taking the shifting geopolitical risks seriously and adapting accordingly.

The survey reports responses from more than 500 senior risk management executives in the international education, IT, manufacturing, construction, government, banking, transportation, non-government organizations (NGO), tourism, education and oil and gas sectors. In addition to today's Lagos, Nigeria event, the survey will be featured at a panel discussion next week in Amman, Jordan.

The full 2018 Clements Worldwide Risk Index, which was conducted online from January to February 2018, is now available at clements.com/riskindex.

Clements Worldwide is a leading insurance provider for expatriates and international organizations. Founded in 1947, Clements offers international car, property, term life, disability, health, specialty, and high-risk insurance in over 170 countries. With offices in Washington, D.C., London, and Dubai, Clements delivers comprehensive and customized coverage, superior customer service, and unparalleled claims response. For more information on the Clements Worldwide Risk Index and the methodology associated with the survey visit www.clements.com/riskindex. To learn more or receive a quote online, visit  www.clements.com .



Attachment

Patricia Loria
Clements Worldwide
2028720060
ploria@clements.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Clements Worldwide via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum